Translational research in central nervous system drug discovery.
Of all the therapeutic areas, diseases of the CNS provide the biggest challenges to translational research in this era of increased productivity and novel targets. Risk reduction by translational research incorporates the "learn" phase of the "learn and confirm" paradigm proposed over a decade ago. Like traditional drug discovery in vitro and in laboratory animals, it precedes the traditional phase 1-3 studies of drug development. The focus is on ameliorating the current failure rate in phase 2 and the delays resulting from suboptimal choices in four key areas: initial test subjects, dosing, sensitive and early detection of therapeutic effect, and recognition of differences between animal models and human disease. Implementation of new technologies is the key to success in this emerging endeavor.
Hurko
Orest
O
Translational Research, Wyeth, Collegeville, Pennsylvania 19426, USA. hurkoo@wyeth.com
Ryan
John L
JL
D000818:Animals; D002491:Central Nervous System Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002493:Central Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D013678:Technology, Pharmaceutical / Q000379:methods*
D002491:Central Nervous System Agents